Millions of Americans Modify GLP-1 Doses as High Costs and Shortages Persist

Nearly half of American adults taking GLP-1 medications are not taking them as prescribed, according to a report from the U.S. Centers for Disease Control and Prevention. The findings underscore widespread nonadherence and dosage modification across the country as millions turn to the blockbuster therapies for type 2 diabetes and obesity management.

According to federal survey data, approximately 44 percent of adults using glucagon-like peptide-1 receptor agonists reported altering their regimens. The most common variation was skipping doses, reported by 28 percent of users, while other patients delayed filling prescriptions, reduced their dosage amounts, or rationed their remaining supplies.

Financial strains and recurring supply bottlenecks were cited as the primary reasons behind the altered dosing habits. Roughly 38 percent of individuals who changed how they take the drugs pointed to high out-of-pocket costs, while 36 percent attributed modifications to availability issues and shortages. Another 12 percent of patients reported reducing or stopping their medication because of gastrointestinal side effects.

The analysis documented significant disparities across age groups, with younger adults far more likely to modify their prescribed routines. Among patients aged 18 to 39, about 54 percent reported altering their use, compared with 30 percent of patients aged 65 and older. Furthermore, 58 percent of younger adults cited cost as a primary obstacle, compared to only 20 percent of senior patients.

Regimen modifications were also substantially higher among individuals using unapproved compounded versions of GLP-1 therapies. While 36 percent of patients on commercial brand-name formulations altered their usage, that figure climbed to 62 percent among those taking compounded alternatives. Steep list prices and persistent commercial shortages have led many consumers toward telehealth platforms and specialty compounding pharmacies for lower-cost options.

Compounded drugs do not undergo the standard premarket safety and efficacy evaluations required for Food and Drug Administration approval. Regulators and medical societies have cautioned that compounded preparations carry heightened risks of dosing errors, inconsistent ingredient concentrations, and sterility issues. When patients must draw variable quantities from multi-dose vials using individual syringes, confusion over correct volumes can further amplify the risk of misdosing.

Medical experts warn that straying from prescribed GLP-1 schedules can undermine treatment goals and introduce health risks. These medications mimic natural metabolic hormones to stimulate insulin production, slow stomach emptying, and regulate appetite signals. Inconsistent dosing or abrupt pauses can trigger rapid rebounds in blood sugar levels and weight regain, blunting the long-term clinical benefits of therapy.

The findings reflect wider systemic hurdles surrounding the accessibility of modern weight-loss and diabetes treatments in the United States. Even as clinical demand continues to climb, many private health insurers and public programs restrict coverage or exclude anti-obesity medications entirely. Without robust insurance assistance, list prices for brand-name injectables can exceed one thousand dollars per month.

Public health researchers stress that improving medication adherence will depend on expanding drug affordability and reinforcing domestic supply stability. Health providers are also encouraged to initiate direct conversations with patients about adherence barriers, ensuring individuals do not covertly ration doses without clinical supervision. As scrutiny over alternative compounding channels deepens, policymakers face growing urgency to ensure reliable and safe access to essential metabolic treatments.